Next Article in Journal
Nanoparticle-Encapsulated Plant Polyphenols and Flavonoids as an Enhanced Delivery System for Anti-Acne Therapy
Next Article in Special Issue
Intrathecal Morphine Versus Other Techniques for Postoperative Pain Management in the Context of Multimodal Analgesia: A Meta-Analysis
Previous Article in Journal
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Previous Article in Special Issue
Opioid System and Epithelial–Mesenchymal Transition
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)?

by
Shaul Schreiber
1,2,3,
Lee Keidan
4,5 and
Chaim G. Pick
3,4,5,6,*
1
Department of Psychiatry, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel
2
Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel
3
Faculty of Medicine & Health Sciences, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6905904, Israel
4
Sylvan Adams Sports Institute, Tel Aviv University, Tel Aviv 6905904, Israel
5
Department of Anatomy and Anthropology, Faculty of Medicine & Health Sciences, Tel Aviv University, Tel Aviv 6905904, Israel
6
Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases, Tel-Aviv University, Tel-Aviv 6905904, Israel
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(2), 208; https://doi.org/10.3390/ph18020208
Submission received: 1 December 2024 / Revised: 23 January 2025 / Accepted: 27 January 2025 / Published: 3 February 2025

Abstract

Background/Objectives: Approximately one in five individuals will experience major depressive disorder (MDD), and 30% exhibit resistance to standard antidepressant treatments, resulting in a diagnosis of treatment-resistant depression (TRD). Historically, opium was used effectively to treat depression; however, when other medications were introduced, its use was discontinued due to addiction and other hazards. Recently, kappa opioid receptor (KOR) antagonism has been proposed as a potential mechanism for treating TRD. The main research question is whether commonly used psychotropic medications possess KOR antagonist properties and whether this characteristic could contribute to their efficacy in TRD. Methods: We investigated the antinociceptive effects of many psychotropic medications and their interactions with the opioid system. Mice were tested with a hotplate or tail-flick after being injected with different doses of these agents. Results: The antidepressants mianserin and mirtazapine (separately) induced dose-dependent antinociception, each yielding a biphasic dose–response curve. Similarly, the antidepressant venlafaxine produced a potent effect and reboxetine produced a weak effect. The antipsychotics risperidone and amisulpride exhibited a dose-dependent antinociceptive effect. The sedative–hypnotic zolpidem induced a weak bi-phasic dose-dependent antinociceptive effect. All seven psychotropic medications elicited antinociception, which was reversed by the non-selective opiate antagonist naloxone and, separately, by the kappa-selective antagonist Nor-BNI. Conclusions: Clinical studies are mandatory to establish the potential efficacy of augmentation of the treatment with antidepressants with these drugs in persons with treatment-resistant depression and the optimal dosage of medications prescribed. We suggest a possible beneficial effect of antidepressants with kappa antagonistic properties.
Keywords: treatment-resistant depression; opioids; mice; antinociception; mianserin; mirtazapine; venlafaxine; reboxetine; risperidone; amisulpride; zolpidem treatment-resistant depression; opioids; mice; antinociception; mianserin; mirtazapine; venlafaxine; reboxetine; risperidone; amisulpride; zolpidem

Share and Cite

MDPI and ACS Style

Schreiber, S.; Keidan, L.; Pick, C.G. A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? Pharmaceuticals 2025, 18, 208. https://doi.org/10.3390/ph18020208

AMA Style

Schreiber S, Keidan L, Pick CG. A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? Pharmaceuticals. 2025; 18(2):208. https://doi.org/10.3390/ph18020208

Chicago/Turabian Style

Schreiber, Shaul, Lee Keidan, and Chaim G. Pick. 2025. "A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)?" Pharmaceuticals 18, no. 2: 208. https://doi.org/10.3390/ph18020208

APA Style

Schreiber, S., Keidan, L., & Pick, C. G. (2025). A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? Pharmaceuticals, 18(2), 208. https://doi.org/10.3390/ph18020208

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop